Trans-endothelial hyper-permeability caused by numerous agonists is dependent on Heat shock 22 protein 90 (Hsp90) and leads to endothelial barrier dysfunction (EBD). Inhibition of Hsp90 23 protects and restores trans-endothelial hyper-permeability. Hyper-acetylation of Hsp90, as by 24 inhibitors of histone deacetylase (HDAC), suppresses its chaperone function and mimics the 25 effects of Hsp90 inhibitors. In this study we assessed the role of HDAC in mediating LPS-26 induced trans-endothelial hyper-permeability and acute lung injury (ALI). We demonstrate that 27 HDAC inhibition protects against LPS-mediated EBD. and HDAC6 by specific siRNAs provided significant protection against LPS-induced EBD. 34
INTRODUCTION 45
Lipopolysaccharide (LPS), a major component of the bacterial wall cell membrane, is released 46 in the bloodstream during infection after bacteria are lysed by white blood cells (8, 44) . LPS 47 binds the TLR4 receptor complex on endothelial cells and induces multiple signaling pathways 48 that lead to the production and release of pro-inflammatory cytokines and endothelial barrier 49 dysfunction (EBD) (19, 45, 54) . Inflammation and EBD are the primary causes of acute lung 50 injury (ALI), and acute respiratory distress syndrome (ARDS) (3, 18, 44, 46) . 51
The ATP-dependent molecular chaperone, Heat shock protein 90 (Hsp90), plays a central role 52
in LPS-mediated EBD (4, 16). LPS potentiates Hsp90 chaperone function by inducing pp60
Src -53 dependent Y300 phosphorylation of Hsp90 (9). Inhibitors of Hsp90 block LPS-induced Y300 54 phosphorylation in cultured human lung microvascular endothelial cells (HLMVEC) (9) and 55 prolong survival, attenuate inflammation and reduce lung injury in a murine model of LPS-56 induced ALI/ARDS (15). Long-term treatment (>8h) with small molecule inhibitors of Hsp90 57 causes destabilization and ubiquitin-mediated degradation of numerous client proteins, such as 58
Akt and pp60
Src (10, 21, 24, 55) . However, even short-term treatment (<4h) with Hsp90 59 inhibitors attenuates LPS-induced RhoA activation and signaling and protects against LPS-60
mediated EBD in HLMVEC (31). 61
Histone deacetylases (HDAC) remove acetyl groups from the ε-amino group of lysine residues 62 in numerous histone and non-histone proteins such as Hsp90 (11, 61) . In humans, there are 18 63 characterized HDAC distributed into four classes. HDAC3, a class I HDAC, is primarily a nuclear 64 protein that shuttles to the cytoplasm when phosphorylated (53, 61), localizes to the plasma 65 membrane and is a substrate of Src (39). Conversely, HDAC6 is primarily a cytoplasmic protein 66 and a unique member of class II HDAC (12). HDAC6 acetylation results in nuclear translocation 67 and regulation of gene expression (38) . HDAC inhibitors exhibit anti-inflammatory properties by 68 suppressing pro-inflammatory cytokine production (6, 22, 30, 59 ) and reducing disease severity 69 9 in HLMVEC monolayer TER, suggesting that HDAC activity and function is necessary for LPS-169 induced endothelial hyper-permeability. 170
HDAC inhibition attenuates LPS-induced Hsp90 activation and chaperone function. Hsp90 plays 171
a central role in LPS-mediated EBD. Therefore, we hypothesized that the HDAC effects on EBD 172 may involve Hsp90. Confluent HLMVEC were pretreated with vehicle or the specific Hsp90 173 inhibitor, AUY-922, followed by exposure to LPS (1 EU/ml). At the end of treatment, cells were 174 lysed and total cellular HDAC activity was measured, as described in Materials and Methods. 175 LPS alone increased HDAC activity. AUY-922 did not affect neither the basal nor the LPS-176 induced HDAC activity (Figure 2A ), suggesting that Hsp90 functions downstream of HDAC. To 177 prove this, we then examined the effects of HDAC inhibitors on Hsp90 activation and function. 178
LPS induces Hsp90-Y300 phosphorylation via pp60
Src to activate Hsp90 and potentiate its 179 chaperone function. If HDACs act is upstream of Hsp90, then inhibition of HDAC function would 180 affect LPS-induced Hsp90-Y300 phosphorylation. To test this, we pre-treated HLMVEC with 181 panobinostat or TSA followed by exposure to LPS. Both panobinostat and TSA completely 182 blocked LPS-induced Y300 phosphorylation of Hsp90 ( Figure 2B ). 183
Acetylation of Hsp90 suppresses its chaperone function. Therefore, we determined whether 184 HDAC inhibition acetylates Hsp90 in HLMVEC. Treatment with panobinostat for 2h increased 185 Hsp90 acetylation ( Figure 2C ). Furthermore, panobinostat completely abolished the LPS-186 induced and Hsp90-dependent phosphorylation of Akt, an Hsp90 client protein ( Figure 2D) . 187
Taken together, the data in Figure 2 Figure 3A) . Furthermore, LPS induces di-198 phosphorylation of MLC2 in HLMVEC and this induction was completely blocked by either 199 panobinostat or TSA ( Figure 3B and 3C ). This data suggests that HDAC inhibition blocks RhoA 200 activity and signaling, most likely by attenuating Hsp90 chaperone function. 201
202

HDAC3 is involved in LPS-induced EBD. HDAC3 and HDAC 6 have been reported to interact 203
with Hsp90. Therefore, we hypothesized that they may be selectively involved in LPS-induced 204 EBD. Confluent HLMVEC were exposed to vehicle or LPS (1 EU/ml) for 2h, lysed, HDAC3 was 205 immunoprecipitated and HDAC activity was measured as described in Materials and Methods. We then determined whether inhibition of HDAC3 blocks the LPS-mediated decrease in TER. 211
To that end, we employed the HDAC3-selective inhibitor, RGFP966. Pretreatment with 212 RGFP966, at a concentration similar to those reported in the literature without apparent toxic 213 effects (57), moderately but significantly reduced total HDAC activity ( Figure 4C ), in a 214 concentration-dependent manner, but nearly abolished HDAC3 activity, also in a concentration-215 dependent manner ( Figure 4D ). Importantly, pre-treatment with RGFP966 significantly 216 attenuated the LPS-induced decrease in TER ( Figure 4E ). This data suggests that HDAC3 217 plays a significant role in LPS-mediated EBD. 218
219
HDAC6 inhibition attenuates the LPS-mediated EBD. HDAC6 interacts with, and regulates 220
Hsp90 chaperone function (7, 50) . Inhibition of HDAC6 blocks endothelial hyper-permeability 221 induced by thrombin (49). Therefore, we hypothesized that LPS modulates HDAC6 activity and 222 that inhibition of HDAC6 may prevent the LPS-induced endothelial hyper-permeability. 223
Confluent HLMVEC were exposed to vehicle or LPS (1 EU/ml) for 1 or 2h, lysed, HDAC6 was 224 immunoprecipitated and HDAC activity was measured as described in Materials and Methods. 225 LPS did not affect basal HDAC6 activity ( Figure 6A ). Similarly, LPS did not affect the expression 226 of either HDAC3 or HDAC6 proteins (data not shown). We then determined whether HDAC6 is 227 involved in the LPS-mediated decrease in TER. Pretreatment with the HDAC6-selective 228 inhibitor, tubastatin A, for 2h and at a concentration similar to those reported in the literature 229 without apparent toxic effects (17), moderately but significantly reduced total HDAC activity 230 ( Figure 5B ), in a concentration-dependent manner, but nearly abolished HDAC6 activity, also in 231 a concentration-dependent manner ( Figure 5C ). Furthermore, pre-treatment with tubastatin A 232 blocked the LPS-induced decrease in TER ( Figure 5D ). This data suggests that even though 233 HDAC6 activity is not affected by LPS, HDAC6 plays an important part in LPS-mediated EBD. 234
235
Combined inhibition of HDAC 3 and 6 attenuates LPS-mediated EBD. As shown in Figures 4 236
and 5, selective inhibition of either HDAC3 or HDAC6 provides partial but significant protection 237 against LPS-mediated EBD. Therefore, we investigated the effect of combined inhibition of 238 HDAC 3 and 6. HLMVEC were exposed to 5μM each of RGFP966 and tubastatin for 2h, 239 followed by LPS (1EU/ml). This treatment essentially abolished the LPS-induced MLC2 240 phosphorylation ( Figure 6A ) and Hsp90 chaperone function, as reflected in Akt phosphorylation12 ( Figure 6B ). To further assess the combined role of HDAC 3 and 6 in LPS-mediated EBD, 242 HLMVEC were transfected with siRNAs against HDAC 3 and 6. The siRNA produced >80% 243 inhibition of HDAC3 and HDAC6 expression ( Figure 7A and 7B) . Subsequently, the two siRNAs 244 were added to HLMVEC freshly plated on ECIS arrays. TER was monitored starting 24h later 245 and for comparison purposes, data is presented normalized to the 24h values. Over the next 246 20h HLMVEC lacking most of HDAC3 and 6 exhibited faster proliferation ( Figure 7C ). At 48h 247 post plating, LPS (1 EU/ml) was added to the arrays and, for comparison purposes, TER data 248 was again normalized to the value just prior to LPS addition. Cells lacking HDAC3 and 6 were 249 significantly more resistant to LPS than cells transfected with scrambled siRNA ( Figure 7D ). 250
251
Combined inhibition of HDAC 3 and 6 attenuates LPS-mediated ALI. 252
To investigate whether the EBD protective effects of HDAC3 and 6 inhibitors conferred similar 253 protection against LPS-induced ALI, mice were injected intra-peritoneally with 10mg/kg each of 254 RGFP966 and Tubastatin. After 24h, 1.5mg/kg LPS was given intratrachelly to mice under 255 anesthesia and bronchoalveolar lavage fluid (BALF) was collected 24h post-LPS instillation. 256 Cellular infiltration into alveoli was quantified by counting number of cells in BALF. LPS induced 257 a profound and significant increase in leukocyte infiltration compared to vehicle treatment; 258 however, BALF from mice pre-treated with RGFP966 and Tubastatin exhibited significantly less 259 cellular infiltration ( Figure 8A ). Similarly, a partial but significant attenuation of BALF protein 260 concentration was observed in mice pre-treated with RGFP966 and Tubastatin, compared to 261 mice treated with LPS ( Figure 8B ). Histological examination of lung tissue stained with H&E 262 revealed significant protection in lungs of mice treated with RGFP966 and Tubastatin from the 263 LPS-induced structural changes, reflected in septal thickness and cellular infiltration ( Figure 8C , 264 arrows), whereas MPO staining demonstrated the granulocytic nature of the invading cells 265 ( Figure 8D ). When quantified with respect to Lung Injury index (42), the combination of HDAC3 266 and 6 inhibitor treatment effectively protected against LPS-induced lung pathology ( Figure 8E ). 267
Together, data in Figure 8 indicate that combined inhibition of HDAC 3 and 6 protects against 268 LPS-mediated ALI. 269
DISCUSSION 270
Lysine acetylation is fine-tuned by the opposing actions of two families of enzymes, histone 271 acetyltransferases (HAT) and histone deacetylases (HDAC). The HAT adds an acetyl group 272 whereas HDAC removes acetyl groups from the ε-amino group of lysine residues (11, 61). In 273 humans, there are 18 characterized HDAC which are distributed in four classes based on 274 function and DNA sequence similarity (20). Despite their name, HDAC target not only histone, 275 but also many non-histone proteins both in the nucleus and the cytoplasm and regulate a variety 276 of functions including transcription, cytoskeletal polymerization and signaling pathways (28, 30, 277 51, 61) . 278
Inhibition of HDAC activity exhibit immunosuppressive and anti-inflammatory properties by 279 reducing cytokine production in both humans and mice (6, 22, 30, 59) . HDAC inhibition also 280 reduces disease severity in several animal models of inflammatory and autoimmune diseases 281 and inhibition of HDAC would suppress Hsp90 chaperone function. We also found that inhibition 296 of HDAC activity blocked LPS-induced Y300 phosphorylation of Hsp90 suggesting that HDAC 297 inhibition also attenuates LPS-mediated and Src-dependent phosphorylation and activation of 298 Hsp90 (9). Thus we propose that prevention of EBD by HDAC inhibitors is achieved by 299 disrupting Hsp90 chaperone function. This is supported by directly demonstrating that HDAC 300 inhibition prevents LPS-induced Akt phosphorylation ( Figure 2D ). Akt is an Hsp90 client protein 301 and its activation (phosphorylation) by LPS (58) or other agonists is Hsp90-dependent. 302
The Rho-ROCK pathway modulates cell-cell adhesion and vascular permeability by regulating 303 myosin-mediated contractile forces (13, 25) . LPS-induced RhoA activity requires activation of 304
Src, an Hsp90 client protein. Induction of RhoA activity phosphorylates ROCK which in turn 305
phosphorylates MLC leading to increase in myosin-mediated contractile forces and EBD (1, 25) . 306
In HLMVEC, two ROCK inhibitors, Y27632 and GSK429286, block MLC phosphorylation and 307 provide significant protection against LPS-mediated decrease in TER (31). Also, inhibition of Src 308 or Hsp90 completely abolished the LPS-induced RhoA activity and MLC phosphorylation in 309 HLMVEC (31). Since HDAC inhibition suppresses Hsp90 function we hypothesized and 310 demonstrated that treatment with HDAC inhibitor should also attenuate RhoA activity and MLC 311 phosphorylation. We also demonstrated that among HDACs, HDAC3 and HDAC6 are major 312 contributors to the LPS-induced EBD and ALI. 313
HDAC3, a class I HDAC, is primarily a nuclear protein that regulates transcription (60). 314
Phosphorylation at serine 424 increases HDAC3 activity and translocates HDAC3 to the 315 cytoplasm where it interacts with and deacetylates Hsp90 and promotes its chaperone function 316 (62). Cytoplasmic HDAC3 is a substrate of, and regulated by, Src, and has been shown to 317 localize at the plasma membrane (39). Consistent with these observations, our data 318 demonstrates that LPS selectively induces HDAC3 activity by inducing serine 42416 phosphorylation and that selective inhibition of HDAC3 protects against LPS-induced decrease 320 in TER indicating that HDAC3 activity plays a crucial role in LPS-mediated EBD. 321
Recently, the HDAC6 specific inhibitor, tubacin, was shown to suppress thrombin-induced EBD 322 in human pulmonary arterial cells (49). HDAC6 is a unique member of class II because it 323 contains two homologous, fully functional catalytic domains. The C-terminal catalytic domain of 324 HDAC6 possesses α-tubulin deacetylase activity and regulates microtubule dynamics (12, 27) . 325 HDAC6 is primarily cytoplasmic and interacts with and deacetylates Hsp90 (5, 35). The HAT, 326 p300, acetylates HDAC6, promotes nuclear translocation and regulates gene expression (38) . 327
Our data demonstrates that LPS does not induce HDAC6 activity (data not shown) however, 328 selective pharmacologic or genetic inhibition of HDAC6 protects against the LPS-induced 329 decrease in TER. This suggests that basal HDAC6 activity is critical in inducing LPS-mediated 330 EBD and that inhibition of HDAC6 provides a possible strategy to protect against LPS-mediated 331
EBD. 332
Both HDAC3 and HDAC6 are involved in gene expression, protein function, kinase signaling 333 and cytoskeletal changes in endothelial cells (2, 32-34, 41, 49, 52, 63) . In the cytoplasm, both 334 HDAC3 and HDAC6 interact with the molecular chaperone Hsp90 and regulate its chaperone 335 activity (47). Therefore, we speculated that combined inhibition of HDAC 3 and 6 might provide 336 better protection against LPS-mediated EBD. Our data demonstrates that combined 337 pharmacologic or genetic inhibition of HDAC 3 and 6 provides significant protection against 338
LPS-mediated EBD in HLMVEC and against LPS-induced ALI in mice. 339
Binding of LPS to the endothelial cells elicits a broad cellular response including induction of 340 kinase signaling pathways, production of pro-inflammatory cytokines, cytoskeletal remodeling 341 and loss of cell-cell adhesion. Together these effects cause an increase in trans-endothelial 342 permeability and lead to EBD and ALI. Hsp90 regulates the stability and activity of many 343 proteins in these pathways. Our present data uncovers a novel mechanism of LPS-induced 344 endothelial hyper-permeability (Figure 9) vehicle, LPS (1 EU/ml), 1μM panobinsotat, or 1μM panobinsotat for 2h followed by exposure to 548 LPS (1 EU/ml) for 2h. Cells were then lysed and immunoblotted for phosho-Akt (S473) and Akt. 549
Densitometric analysis was carried out and the ratio of pAkt to Akt was plotted. 550 dishes. When confluent, the cells were treated with either PBS or LPS (1 EU/ml) for 2h. Cells 565 were then lysed, HDAC3 was immunoprecipitated and HDAC activity was measured using the 566 Flour-de-lys HDAC activity assay. (n=4; *: p<0.05). B) HLMVEC were treated as above. Cells 567 were lysed, HDAC3 was immunoprecipitated and then immunoblotted for phospho-serine 424 568 and HDAC3. (n=3; *: p<0.05). C,D) HLMVEC were grown in 100mm dishes. When confluent, 569 the cells were treated with the indicated concentrations of the HDAC3 selective inhibitor, 570 RGFP966 for 2h and total HDAC (C), as well HDAC3 activity (D) was measured, as described 571 previously (n=4; *: P<0.05 from vehicle). E) HLMVEC were grown to confluence on ECIS arrays 572 (8W10E+). Once a constant resistance was attained, the cells were treated with either vehicle 573 (0.1% DMSO) or 5μM RGFP966 (RGF) for 2h. LPS (1 EU/ml) was then added as indicated and 574 TER values were measured using an ECIS Zθ. *: p<0.05 from vehicle; #: p<0.01 from LPS. 575 576
Figure 5 577
HDAC6 inhibition protects against LPS-induced EBD. A) HLMVEC were grown in 100mm 578 dishes. When confluent, the cells were treated with either PBS or LPS (1 EU/ml) for 2h. Cells 579 were then lysed, HDAC6 was immunoprecipitated and HDAC activity was measured using the 580 Flour-de-lys HDAC activity assay. B, C) HLMVEC were grown in 100mm dishes. When 581 confluent, the cells were treated with the indicated concentrations of the HDAC6 selective 582 inhibitor, tubastatin for 2h and total HDAC (B), as well HDAC6 activity (C) were measured, as 583 described previously (n=4; *: P<0.05 from vehicle). D) HLMVEC were grown to confluence on 584 ECIS arrays (8W10E+). Once a constant resistance was attained, the cells were treated with 585 either vehicle (0.1% DMSO) or 5 μM Tubastatin (Tub) for 2h. LPS (1 EU/ml) was then added as 586 
